BCTK Raises ￥60M in Series A Funding Round

According to PEdaily.cn, Suzhou Bochuang Tongkang Bio-Engineering Co., Ltd. ("BCTK") has completed its Series A round of financing, with participation from Ningbo Qingyi Qiusher Investment, Kunshan Hi-tech Venture Capital, and WinX Capital as the financial adviser, with a total amount of nearly 60 million yuan (including the A1 financing round). 

Proceeds from the latest round will be used for further R&D and industrialization of BCTK's innovative preparations and devices for drug delivery in the surgical treatment of cancer.

BCTK is located in the Biomedical Industrial Park of Kunshan High-Tech Zone, Jiangsu. It is a member of the first batch of biopharmaceutical innovation alliance enterprises focusing on small nucleic acids. The company is committed to developing regenerative medicine and new materials that can replace and repair human tissues and organs, and providing products of drug delivery with a combination of drugs and medical devices.

BCTK's main pipelines focus on surgical treatments for cancer, such as high-value consumables required during the surgery, including absorbable hemostasis material, functional materials for tissue closure, prevention of adhesion and infection, in situ tissue regeneration. It also provides formulations of slow-release and controlled release drug delivery in postoperative treatment for breast cancer, lung cancer, and glioma of the brain.

At present, BCTK has built two technology platforms, one is for regenerative medicine and new material medical equipment, the other is for the combination of medical devices and preparations of drug delivery. The core technology has acquired the national invention patent and has a strong technical barrier. With foreign cooperation, BCTK has also established a platform for developing gene therapy drugs.

Based on the R&D of bio-nano materials, BCTK has developed the drug delivery system of small nucleic acids, using drug releasing films and microspheres to maintain drug release over a long period. The company is working on the pharmacodynamics of animal models of several products.